TY - JOUR
T1 - Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression
AU - Kilic, Ozgun
AU - De Souza, Marcos R.Matos
AU - Almotlak, Abdulaziz A.
AU - Wang, Yiao
AU - Siegfried, Jill M
AU - Distefano, Mark D.
AU - Wagner, Carston R.
N1 - Publisher Copyright:
© 2020 American Chemical Society.
PY - 2020/9/24
Y1 - 2020/9/24
N2 - Overexpression of the epidermal growth factor receptor (EGFR) on various cancers makes it an important target for cancer immunotherapy. We recently demonstrated that single-chain variable fragment-based bispecific chemically self-assembled nanorings (CSANs) can successfully modify T cell surfaces and function as prosthetic antigen receptors (PARs) allowing selective targeting of tumor antigens while incorporating a dissociation mechanism of the rings. Here, we report the generation of anti-EGFR fibronectin (FN3)-based PARs with high yield, rapid protein production, predicted low immunogenicity, and increased protein stability. We demonstrated the cytotoxicity of FN3-PARs successfully while evaluating FN3 affinities, CSAN valencies, and antigen expression levels. Using an orthotopic breast cancer model, we showed that FN3-PARs can suppress tumor growth with no adverse effects and FN3-PARs reduced immunosuppressive programmed cell death ligand-1 (PD-L1) expression by downregulating EGFR signaling. These results demonstrate the potential of FN3-PARs to direct selective T cell-targeted tumor killing and to enhance antitumor T cell efficacy by modulating the tumor microenvironment.
AB - Overexpression of the epidermal growth factor receptor (EGFR) on various cancers makes it an important target for cancer immunotherapy. We recently demonstrated that single-chain variable fragment-based bispecific chemically self-assembled nanorings (CSANs) can successfully modify T cell surfaces and function as prosthetic antigen receptors (PARs) allowing selective targeting of tumor antigens while incorporating a dissociation mechanism of the rings. Here, we report the generation of anti-EGFR fibronectin (FN3)-based PARs with high yield, rapid protein production, predicted low immunogenicity, and increased protein stability. We demonstrated the cytotoxicity of FN3-PARs successfully while evaluating FN3 affinities, CSAN valencies, and antigen expression levels. Using an orthotopic breast cancer model, we showed that FN3-PARs can suppress tumor growth with no adverse effects and FN3-PARs reduced immunosuppressive programmed cell death ligand-1 (PD-L1) expression by downregulating EGFR signaling. These results demonstrate the potential of FN3-PARs to direct selective T cell-targeted tumor killing and to enhance antitumor T cell efficacy by modulating the tumor microenvironment.
UR - http://www.scopus.com/inward/record.url?scp=85091596702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091596702&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.0c00489
DO - 10.1021/acs.jmedchem.0c00489
M3 - Article
C2 - 32852209
AN - SCOPUS:85091596702
SN - 0022-2623
VL - 63
SP - 10235
EP - 10245
JO - Journal of medicinal chemistry
JF - Journal of medicinal chemistry
IS - 18
ER -